Hydromorphone half-life
Immediate-release labeling supports a parent hydromorphone half-life a little over two hours.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. The shaded band shows the reported half-life range. This is a mathematical visualization, not a personal concentration estimate.
Hydromorphone: evidence and interpretation notes
Parent drug, metabolites, and formulation
Immediate-release labeling supports a parent hydromorphone half-life a little over two hours. Renal handling of metabolites and formulation differences belong outside that single parent curve.
The plotted input is 2.3 hours for Hydromorphone. It is a normalized comparison line, not a reconstruction of a measured blood concentration or a forecast of effects.
Hydromorphone should be read with attention to parent-drug decline, active metabolites, formulation, tolerance, and overdose risk. The curve is useful for comparing elimination speed, but it cannot answer analgesic, conversion, safety, or monitoring questions.
What each source contributes
- DailyMed: HYDROMORPHONE HYDROCHLORIDE TABLET [ST. MARY’S MEDICAL PARK PHARMACY]. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- PubChem: Hydromorphone. This identity record confirms names and compound identity and does not supply a human half-life.
- Opioid pharmacology. This supporting literature record adds compound-specific background and is used only within the limits of its design.
For Hydromorphone, the numerical model is tied most closely to DailyMed: HYDROMORPHONE HYDROCHLORIDE TABLET [ST. MARY’S MEDICAL PARK PHARMACY]. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.
Why the range stays visible
The 2-to-3-hour range is retained beside the 2.3-hour input for Hydromorphone. It is not an uncertainty slider or a personalized prediction; it shows that the cited literature does not reduce to one invariant value.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 2.3 h as a representative input for Hydromorphone. In the simplified model, about 0.1% remains after 24 hours and about 3% remains after five half-lives, or roughly 11.5 h.
This is a short curve. The modeled amount changes noticeably over the same day, while effects, metabolites, and safety questions can still follow a different timeline. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
opioid context
Opioid pharmacokinetics can differ between parent compounds and metabolites, and timing can vary by route, formulation, and individual clearance.
- Half-life is not a measure of respiratory risk or functional impairment.
- Active metabolites can matter even when the parent compound declines.
- Extended-release products require separate source context.
ComparisonTimeline checkpoints and nearby profiles
Hydromorphone timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 6 h | 16.4% | Long-tail portion of the model |
| 12 h | 2.69% | Low modeled remainder, not a clearance guarantee |
| 24 h | 0.07% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Hydromorphone within the opioid group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Codeine (3 h)
- Morphine (2 h)
- Heroin (6 min)
- Meperidine (3 h)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 2.3 h |
|---|---|
| Reported range | 2 h to 3 h |
| Curve type | Normalized, first-order decline |
Selection note: Immediate-release labeling supports a parent hydromorphone half-life a little over two hours. Renal handling of metabolites and formulation differences belong outside that single parent curve.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: HYDROMORPHONE HYDROCHLORIDE TABLET [ST. MARY'S MEDICAL PARK PHARMACY].Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Identity record PubChem Compound Summary: Hydromorphone.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
- Research abstract PubMed: Opioid pharmacology.Supporting literature record. Its role and study design should be read from the linked source before applying any numerical finding.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the opioid group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.